Research into epigenetic alterations involved in prostate cancer has identified BAZ2A as a potential marker for disease aggression and metastasis. BAZ2A upregulation in prostate cancer is post-transcriptional, resulting from downregulation of microRNA-133a. In PC3 metastatic prostate cancer cells, BAZ2A knockdown impaired proliferation, viability, invasion and migration. BAZ2A and the simiiarly upregulated EZH2 coordinated a metastatic pattern of epigenetic gene silencing. In tissue microarray analyses, BAZ2A expression was an independent predictor of disease recurrence, notably in cases of intermediate-risk disease.
References
Gu, L. et al. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat. Genet. 10.1038/ng.3165
Rights and permissions
About this article
Cite this article
Epigenetics in prostate cancer aggression and recurrence. Nat Rev Clin Oncol 12, 64 (2015). https://doi.org/10.1038/nrclinonc.2014.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.230